Friday, July 10, 2026

Drug profile · INN

aminolevulinic acid hydrochloride

aminolevulinic acid hydrochloride (ALABEL/ALAGLIO) is a dna inhibitor. Route of administration: topical. Current US regulatory status: approved.

FDA: approved PMDA: approved
US status approved
Patents linked 0
Pipeline programs 1
News articles 0
Drug details — aminolevulinic acid hydrochloride
US status
approved
Class
Route
TOPICAL
Patents
0
Programs
1
Data quality
0.84

Quick answer

aminolevulinic acid hydrochloride (ALABEL/ALAGLIO) is a dna inhibitor. Route of administration: topical. Current US regulatory status: approved.

Key facts

INN aminolevulinic acid hydrochloride
Brand ALABEL/ALAGLIO
Mechanism DNA inhibitor
Target DNA
Route TOPICAL
Formulation SOLUTION

Mechanism of action

DNA inhibitor

Primary target: DNA

Approval history

Authority Status Date
FDA approved
PMDA approved

Pipeline programs

  1. LEO 90105 Phase 2 · LEO Pharma US · Psoriasis Vulgaris

Related & competitor drugs

  1. acyclovir Human herpesvirus 1 DNA polymerase inhibitor
  2. acyclovir sodium Human herpesvirus 1 DNA polymerase inhibitor
  3. azacitidine Antineoplastic and immunomodulating agents (L01)
  4. bleomycin sulfate DNA inhibitor
  5. busulfan Antineoplastic and immunomodulating agents (L01)
  6. capecitabine Antineoplastic and immunomodulating agents (L01)

Frequently asked questions

What is aminolevulinic acid hydrochloride?

aminolevulinic acid hydrochloride (ALABEL/ALAGLIO) is a dna inhibitor. Route of administration: topical. Current US regulatory status: approved.

What is the brand name for aminolevulinic acid hydrochloride?

ALABEL/ALAGLIO is a marketed brand name for aminolevulinic acid hydrochloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of aminolevulinic acid hydrochloride?

aminolevulinic acid hydrochloride has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.